Amylyx Pharmaceuticals made waves in 2022 when its ALS drug Relyvrio became the first FDA-approved treatment with evidence suggesting it slowed the progression of the disease. After adding a Canadian ...

Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What ...

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large events to stay on top of the most pressing changes. The past few years in ...

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

Patients in psychedelic trials often know if they’re taking the study drug or a placebo. But trial design changes could ...

Pharma wants AI agents because they can do more than answer a question. They can choose tools, gather evidence and keep a workflow moving. That promise is pushing the industry closer to autonomous R&D ...

Job cuts continue to climb and pervade the biopharma sector this year, defying hopes that 2024 marked a peak. After shedding more than 14,000 jobs in all of 2024, the industry surpassed 13,000 layoffs ...